Healthcare Active Stocks: Bristol-Myers Squibb (NYSE:BMY), MannKind (NASDAQ:MNKD), Achillion (NASDAQ:ACHN), Johnson & Johnson (NYSE:JNJ), Galena Biopharma (NASDAQ:GALE)

Bristol-Myers Squibb Co. (NYSE:BMY)‘s stock had its “hold” rating reiterated by research analysts at Edward Jones in a report released on Thursday. Bristol-Myers Squibb Co (NYSE:BMY) stock performance was 0.44% in last session and finished the day at $48.00. Traded volume was 6.59million shares in the last session and the average volume of the stock remained 9.19million shares. The beta of the stock remained 0.48. Bristol-Myers Squibb Co (NYSE:BMY) insider ownership is 0.10%.

MannKind Corporation (NASDAQ:MNKD) on May 12 reported financial results for the first quarter ended March 31, 2014. The net loss was $52.1 million, or $0.14 per share, compared with a net loss of $41.0 million, or $0.15 per share for the first quarter of 2013. MannKind Corporation (NASDAQ:MNKD) rose 3.67 percent to $10.73 Monday on volume of 8.89million shares. The intra-day range of the stock was $10.25 to $10.79. MannKind Corporation (NASDAQ:MNKD) has a market capitalization of $4.17billion.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) on June 10 announced the Company has begun dosing ACH-3422, a uridine-analog nucleotide polymerase inhibitor, for seven days in patients with genotype 1 chronic hepatitis C viral infection (HCV) in its ongoing Phase 1 clinical trial. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)’s stock on June 23, 2014 reported a decrease of -4.43% to the closing price of $7.77. Its fifty two weeks range is $2.26-$8.61. The total market capitalization recorded $752.10million. The overall volume in the last trading session was 9.28million shares. In its share capital, ACHN has 96.80million outstanding shares.

Johnson & Johnson (NYSE: JNJ) has joined forces with Vertex Pharmaceuticals Inc. (Nasdaq: VRTX-Free Report) for the worldwide development and commercialization of VX-787. The candidate is being developed for the treatment of influenza. Vertex Pharma will be receiving an upfront payment of $30 million from Johnson & Johnson as per the deal. Johnson & Johnson will enjoy full global development and commercialization rights to VX-787. On Monday, shares of Johnson & Johnson (NYSE:JNJ) dropped -0.49% to close the day at $104.75. Company return on investment (ROI) is 15.00% and its monthly performance is recorded as 3.75%. Johnson & Johnson (NYSE:JNJ) quarterly revenue growth is 10.80%.

Sales haven’t been frequent at RXi Pharmaceuticals Corp (NASDAQ:RXII). In fact, last insider sell was made by Large Shareholder Galena Biopharma, Inc (NASDAQ:GALE), selling 912,500 shares, at a price of $0.19 per share, during Q2 2013.Galena Biopharma Inc (NASDAQ:GALE) stock performance was 4.33% in last session and finished the day at $3.13. Traded volume was 5.18million shares in the last session and the average volume of the stock remained 3.99million shares. The beta of the stock remained 0.87. Galena Biopharma Inc (NASDAQ:GALE) insider ownership is 0.50%.